tiprankstipranks
BioVersys AG (CH:BIOV)
:BIOV
Switzerland Market
BIOV
BioVersys AG
RESEARCH TOOLSreports

BioVersys AG (BIOV) Stock News & Sentiment

2 Followers
BioVersys: Strategic Hackensack Partnership and Pivotal BV100 Phase 3 Underpin Buy Rating and CHF40 Target
Premium
Ratings
BioVersys: Strategic Hackensack Partnership and Pivotal BV100 Phase 3 Underpin Buy Rating and CHF40 Target
2h ago
BioVersys advances TB portfolio as Nature Communications paper underscores AlpE’s resistance‑breaking potential
Premium
Company Announcements
BioVersys advances TB portfolio as Nature Communications paper underscores AlpE’s resistance‑breaking potential
7h ago
BIOV
BioVersys Calls 2026 AGM and Proposes Board Refresh as Late-Stage Pipeline Advances
Premium
Company Announcements
BioVersys Calls 2026 AGM and Proposes Board Refresh as Late-Stage Pipeline Advances
6d ago
BIOV
BioVersys Strengthens Investor Outreach With New IR and Communications Head
Premium
Company Announcements
BioVersys Strengthens Investor Outreach With New IR and Communications Head
11d ago
BIOV
BioVersys AG: Expanding NTM Ansamycin Platform via HMH Partnership Supports Long‑Term Growth and Reiterated Buy Rating
Premium
Ratings
BioVersys AG: Expanding NTM Ansamycin Platform via HMH Partnership Supports Long‑Term Growth and Reiterated Buy Rating
13d ago
BioVersys bolsters anti-NTM pipeline with Hackensack Meridian Health ansamycin deal
Premium
Company Announcements
BioVersys bolsters anti-NTM pipeline with Hackensack Meridian Health ansamycin deal
13d ago
BIOV
BioVersys boosts antibiotic pipeline and cash runway with Phase 3 launch and IPO war chest
Premium
Company Announcements
BioVersys boosts antibiotic pipeline and cash runway with Phase 3 launch and IPO war chest
26d ago
BIOV
More CH:BIOV News >

BIOV News on the Web

BioVersys: Strategic Hackensack Partnership and Pivotal BV100 Phase 3 Underpin Buy Rating and CHF40 Target
TipRanks News
Bullish
BioVersys advances TB portfolio as Nature Communications paper underscores AlpE’s resistance‑breaking potential
TipRanks News
Neutral
BioVersys Calls 2026 AGM and Proposes Board Refresh as Late-Stage Pipeline Advances
TipRanks News
Neutral
BioVersys Strengthens Investor Outreach With New IR and Communications Head
TipRanks News
Neutral
BioVersys AG: Expanding NTM Ansamycin Platform via HMH Partnership Supports Long‑Term Growth and Reiterated Buy Rating
TipRanks News
Bullish
BioVersys bolsters anti-NTM pipeline with Hackensack Meridian Health ansamycin deal
TipRanks News
Bullish
BioVersys boosts antibiotic pipeline and cash runway with Phase 3 launch and IPO war chest
TipRanks News
Bullish
BioVersys AG: FDA-Cleared Phase 3 BV100 Program De‑Risks Path to Approval and Supports Buy Rating
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
CH:BIOV
Sector Average
Media Buzz
This Week3 articles
Weekly Average2 articles
News Sentiment
This Week100%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CH:BIOV’s Media Buzz Sentiment?
3 articles about CH:BIOV were published this week. In an average week, 2 articles are published.
    What is CH:BIOV’s weekly average amount of articles?
    In an average week, 2 articles about CH:BIOV are published.
      What is CH:BIOV’s News Sentiment?
      100% of articles about CH:BIOV were positive this week, compared to its sector average of 68%.
        Healthcare Stocks that are Trending in the News
        AORTArtivion
        STAAStaar Surgical
        IVVDInvivyd
        SLPSimulations Plus
        REPLReplimune Group
        Showing the stocks with the most bullish news sentiment over the past week